Skip to main content

Advertisement

Table 2 The association between clinical variables and 5-FU related enzymes in T1G3 patients treated with BCG

From: Expression level of dihydropyrimidine dehydrogenase is associated with clinical outcome in patients with T1G3 bladder cancer treated with Bacillus Calmette-Guerin

  TS (mean ± SE) DPD (mean ± SE) OPRT (mean ± SE)
Age     
 Less than 70 (n = 14)   10.58 ± 2.12 1.02 ± 0.23 1.91 ± 0.21
 70 or greater (n = 14)   8.23 ± 1.01 1.44 ± 0.26 2.08 ± 0.23
  p value   0.664 0.268 0.964
Gender     
 Men (n = 23) 9.55 ± 1.34 1.35 ± 0.21 1.88 ± 0.15
 Female (n = 5) 8.16 ± 1.21 0.87 ± 0.34 2.18 ± 0.44
  p value   0.748 0.123 0.748
Concomitant CIS     
 Yes (n = 7) 10.80 ± 2.23 0.64 ± 0.21 2.58 ± 0.37
 No (n = 21) 8.94 ± 1.25 1.31 ± 0.21 1.95 ± 0.15
  p value   0.341 0.057 0.054
Multiple disease     
 Yes (n = 19) 8.98 ± 1.22 1.57 ± 0.38 1.77 ± 0.17
 No (n = 9) 10.05 ± 2.26 1.12 ± 0.18 2.26 ± 0.29
  p value   0.770 0.534 0.130
LVI     
 Yes (n = 18) 9.64 ± 1.33 1.03 ± 0.19 1.91 ± 0.19
 No (n = 10) 8.72 ± 1.93 1.64 ± 0.32 2.09 ± 0.23
  p value   0.547 0.055 0.817
  1. SE: standard error; CIS: carcinoma in situ; LVI: lymphovascular invasion; TS: thymidylate synthase; DPD: dihydropyrimidine dehydrogenase; OPRT: orotate phosphoribosyl transferase.